German pharma lobby warns US price rules could impact local drug access
Pharma Deutschland warns that new US price rules may force firms to delay drug launches in Germany. The group says the nation risks falling behind in access.
The Pharma Deutschland association warned on February 11, 2026, that new drug price regulation in the United States 
US could lead pharmaceutical companies to demand higher prices for new drugs in Germany 
DE or to forgo launching them there. This response to the newly announced U.S. measures could delay or prevent the introduction of innovative medicines in Germany and Europe, affecting patient access to new treatments.
US could lead pharmaceutical companies to demand higher prices for new drugs in Germany DE or to forgo launching them there. This response to the newly announced U.S. measures could delay or prevent the introduction of innovative medicines in Germany and Europe, affecting patient access to new treatments.
